CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 1,517	$ 407	$ 2,752	$ 744
Operating expenses:
Research and development	34,535	21,572	87,585	59,359
General and administrative	8,221	6,531	22,082	20,596
Gain on fair value remeasurement of contingent consideration	0	(0)	0	(6,862)
Litigation settlement related loss				15,000
Total operating expenses	42,756	28,103	109,667	88,093
Operating loss	(41,239)	(27,696)	(106,915)	(87,349)
Investment and other income, net	2,979	912	8,792	1,511
Net loss	$ (38,260)	$ (26,784)	$ (98,123)	$ (85,838)
Basic net loss per common share	$ (0.81)	$ (0.57)	$ (2.08)	$ (1.83)
Diluted net loss per common share	$ (0.81)	$ (0.57)	$ (2.08)	$ (1.83)
Shares used in calculating basic net loss per share	47,261	46,916	47,243	46,806
Shares used in calculating diluted net loss per share	47,261	46,916	47,243	46,806
Comprehensive loss:
Net loss	$ (38,260)	$ (26,784)	$ (98,123)	$ (85,838)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	63	305	875	(2,006)
Comprehensive loss	(38,197)	(26,479)	(97,248)	(87,844)
Product development and licensing agreements
Revenues:
Total revenues	2		19	30
Contracts and grants
Revenues:
Total revenues	$ 1,515	$ 407	$ 2,733	$ 714